ASA, MHRA and GPhC warn businesses over unlicensed weight loss drug ads
Three UK regulators have jointly warned businesses against advertising unlicensed weight loss drugs, with the GPhC making clear it will take enforcement action against those who break the rules. The warning covers GLP-1 medicines that have recently received approval and those that have not yet secured a licence at all. It's a signal that the regulatory temperature around weight loss prescribing is rising.
What happened
The Advertising Standards Authority (ASA), the Medicines and Healthcare products Regulatory Agency (MHRA), and the General Pharmaceutical Council (GPhC) have all issued warnings targeting businesses that advertise unlicensed weight loss drugs. The joint nature of this response reflects how seriously the sector is being watched right now.
Two categories of product appear to be in scope. The first covers GLP-1 receptor agonists that have recently been granted a licence, where advertising rules still apply and cannot simply be treated as open-season marketing. The second covers medicines that do not yet hold a licence at all, meaning they have no legal basis to be advertised to the public or to healthcare professionals in a promotional context.
The GPhC, which regulates pharmacists and pharmacy premises in Great Britain, was direct in its position. The regulator said it "will not hesitate to act" against those who break the rules. That phrasing isn't routine corporate language. It's a deliberate signal that enforcement is coming, not a vague future possibility.
Why it matters
The weight loss medicine space has been chaotic for the last two years. Demand for GLP-1 drugs outpaced supply, compounding pharmacies stepped in with unlicensed specials, and a parallel market of online prescribing services emerged to meet patients who couldn't access medicines through standard routes. Some of that activity was legitimate. A lot of it wasn't.
Advertising unlicensed medicines to the public is not a grey area in UK law. It's prohibited. The Medicines Act and associated regulations draw a clear line: a medicine must hold a marketing authorisation before it can be promoted. Advertising a product that lacks that authorisation, or promoting it outside the terms of any licence it does hold, exposes the business and any registered professionals involved to serious consequences.
For pharmacy professionals, the risk doesn't only come from running the ads themselves. A pharmacist who works for a business advertising unlicensed products, or who provides services off the back of that advertising, may find themselves drawn into a fitness to practise investigation. The GPhC standards on professionalism, honesty, and acting within the law apply regardless of whether the pharmacist personally wrote the marketing copy.
The fact that the ASA is involved alongside the MHRA and GPhC also matters. The ASA handles advertising complaints and can refer serious cases to other authorities. Businesses that believe they can run misleading or unlawful advertising and simply take it down if challenged are likely to find that approach doesn't protect them from regulatory consequences further down the line.
There's a broader context here too. GLP-1 prescribing online has attracted significant media attention, and not all of it flattering. Several services have been criticised for inadequate clinical governance, poor patient safety checks, and promotional content that either exaggerates efficacy or downplays risk. Regulators have been under pressure to act, and this joint warning looks like the opening of a sustained enforcement phase rather than a one-off statement.
For anyone working in online pharmacy, prescribing services, or any business that sells or supplies weight loss medicines, the message is not ambiguous. Get your advertising right, or face action from multiple directions simultaneously.
GPhC exam relevance
The GPhC Common Registration Assessment tests understanding of the legal and professional framework pharmacists operate in, not just clinical knowledge. This situation touches several areas candidates should be confident about.
The distinction between licensed and unlicensed medicines matters in practice. An unlicensed medicine can be prescribed, dispensed, and supplied under certain conditions, but it cannot be advertised to the public. Candidates should understand what an unlicensed medicine is, how specials and imports sit within that framework, and what the advertising rules look like in practice.
Professionalism questions in the assessment frequently ask candidates to identify when a situation crosses a professional or legal boundary. A scenario where a pharmacy employer is running advertising for an unlicensed product is the kind of thing that could appear as a case study. The right answer won't be "raise it with marketing" and leave it there. The GPhC expects registrants to recognise when rules are being broken and to act on that, which may include escalating internally, making a referral, or refusing to participate.
The GPhC standards on honesty and professionalism are also relevant. Pharmacy professionals are expected to act within the law and not allow commercial pressures to override their professional obligations. A business telling you that advertising an unlicensed product is fine because everyone else is doing it, or because the medicine will probably get a licence soon, is not a justification that carries any weight with the regulator.
Candidates should also be aware of how the MHRA and ASA function alongside the GPhC. Regulatory co-operation is a feature of how medicines advertising is policed in the UK, and understanding that multiple bodies can have an interest in the same set of facts is useful background for both practice and the assessment.
What's next
Watch whether the GPhC follows up this warning with visible enforcement action. Regulators don't usually publish joint statements like this without some intention to back them up. Fitness to practise cases involving online prescribing and advertising misconduct could well appear over the coming months.
If you're working in a pharmacy or online service that sells GLP-1 medicines, check what your employer is advertising and how. If something looks wrong, you have professional obligations that don't disappear because it's a commercial decision made above your level.
The ASA's rulings on medicine advertising are publicly searchable. Looking at recent adjudications on weight loss products gives a concrete picture of what regulators consider unacceptable, and that's exactly the kind of source that can help you answer applied professional practice questions.
Source: Chemist+Druggist — https://www.chemistanddruggist.co.uk/news/regulation/regulators-issue-warning-on-ads-for-unlicensed-weight-loss-drugs-FLIAIO7GO5C7JCOP6H2LNVI4HQ/